Urgent.News

What's breaking now, across thousands of outlets.

Business

ST Engineering iDirect partners with MBSat for Middle East connectivity

Satellite provider ST Engineering iDirect partnered with MBSat to deploy its Intuition ground system expanding sovereign satellite communications across Oman and Middle Eastern markets

The United States risks losing its digital asset business to Asia and the Middle East due to the ongoing delay in passing the Clarity Act, according to Peter Hughes, the founder and CEO of Apex Group, a global financial firm. Hughes expressed concerns that Europe will not benefit from Washington's setback, as its own rules have been in place since July 1.

He deemed the Clarity Act and its ensuing delay as leading companies to seek alternative solutions outside the United States. Hughes highlighted the rapid progress in Asia and the Middle East, with countries like Bermuda also moving swiftly to establish regulatory frameworks for digital assets. The U.S. Senate's failure to pass the Clarity Act after failing to garner the necessary 60 votes has left uncertainty over how digital assets will be regulated in the largest economy.

Despite this, Hughes remains optimistic about the future of tokenized money market funds, which he believes can attract institutional investment with their higher yield compared to traditional bank savings accounts. He also expects regulated, yield-bearing stablecoins to become a crucial tool for corporate treasuries as regulations become more favorable.

Saudi Arabia's regulatory changes for real estate tokenization and greater foreign participation in its property market present a significant opportunity for Apex Group, as it prepares to tokenize real-world assets in partnership with droppRWA and Tokeny.

Written by urgent.news from CoinDesk's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at vir.com.vn →

More in Business

Innovent displays Phase I trial results for bispecific ADC IBI3001

Biopharmaceutical manufacturer Innovent Biologics showcased Phase I trial results at ESMO 2026 for IBI3001 a bispecific antibody drug conjugate targeting solid tumours

  • Innovent Biologics presents Phase 1 trial results for bispecific ADC IBI3001 at ESMO Congress.
  • 57 patients from China, Australia, and US participated in multinational study.
  • IBI3001 showed favorable safety and 30.2% overall objective response rate in advanced solid tumors.

More from Monday 26 October →